~~<i id='A52CBAD6D4'><strike id='A52CBAD6D4'><tt id='A52CBAD6D4'><pre id='A52CBAD6D4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

explore

author：explore 2025-09-06 08:25:00 - browse：15

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: XBI biotech index, Akero Therapeutics

knowledge

hotspot

explore

entertainment

knowledge

Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb

WSS

MoonLake credibility takes another hit with mid

Senate panel to vote on hospitals, PBMs, prisoner care

The new shift in health care is toward less care

Excited delirium, Elijah McClain, and emergency physicians

The FDA weighs the risks of candy

Medtronic CEO on promising devices for diabetes, hypertension

Wikipedia

explore

knowledge

Continuity nursing helped my family in our darkest PICU moments

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Psychedelics group wrestles with new pharma identity

Paying for Covid pills will soon shift to insurers

Walensky prepares to leave CDC — and Congress — behind

Diversify hospital leadership teams to protect BIPOC patient health

Peter Hotez and the public health issue of online harassment

The FDA weighs the risks of candy

Sports medicine is finally prioritizing gender equality

Biotech incubator Curie.Bio graduates its first startup

hotspot

FDA approves potent Eli Lilly obesity drug, Zepbound

Biden's order seeks to regulate AI risk without stifling innovation

Just how powerful is the placebo effect?

STAT Executive Editor Rick Berke on STAT's 8th birthday

Eli Lilly to pay $200M for Beam’s stake in gene

Readout Newsletter: What happened with Sarepta's Duchenne data

hotspot

explore

entertainment

knowledge